
Japan’s Ministry of Health, Labour and Welfare granted Shonin approval to Zoll Medical‘s intravascular temperature managment device for treating patients with high fevers and brain damage.
The Chelmsford, Mass.-based medical device company’s temperature regulating device is designed to control high fevers in patients with neurological impairment. It provides direct cooling and warming to the circulatory system via a ballon catheter.
In March 2012, Asahi Kasei (TYO:3407) bought out Zoll for $2.2 billion in a move to increase its presence in the medical device market. Currently, Asahi Kasei operates mostly in chemical markets.
Zoll is preparing a clinical trial for a hypothermia treatment and is seeking a recommendation from both the American Heart Assn. and the Japan Resuscitation Council, James Palazzolo, president of Zoll’s California operations, said in a prepared statement.
Last month Zoll was the 1st company to announce a pledge to share data as part of a patient safety initiative spearheaded by Masimo (NSDQ:MASI) CEO Joe Kiani.